Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00032305 · ClinicalTrials.gov registry record · Phase 2
Research Study in Patients With Severe Ulcerative Colitis
A Phase 2 study, sponsored by Facet Biotech.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00032305 is a Phase 2 study that has completed, run by Facet Biotech. The registered enrollment target is 20 participants.
The verdict
NCT00032305, a Phase 2 study, has completed, sponsored by Facet Biotech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate an intravenous (by injection) investigational medication to treat severe ulcerative colitis refractory to steroid therapy. The research is being conducted at up to 8 clinical research sites in the US and is open to both men and women ages 18 to 70 years old. Participants in the study will have a number of visits to a research site. All study-related care and medication is provided to qualified participants at no cost: this includes all visits, examinations and laboratory work.
Interventions
- DRUG Visilizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2002-03 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00032305
The ClinicalTrials.gov registry entry for NCT00032305 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Facet Biotech, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Visilizumab is the first listed.
NCT00032305 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00032305 about?
NCT00032305 is a clinical study titled "Research Study in Patients With Severe Ulcerative Colitis". The purpose of the study is to evaluate an intravenous (by injection) investigational medication to treat severe ulcerative colitis refractory to steroid therapy. The research is being conducted at up to 8 clinical research sites in the US and is open to both men and women ages 18 to 70 years old. P...
What is the current status of trial NCT00032305?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2002-03. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00032305?
The interventions under investigation include: Visilizumab (DRUG).
Who is sponsoring clinical trial NCT00032305?
This trial is sponsored by Facet Biotech, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.